SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Update: AbbVie headquarters building in California
Deals
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline
Monday’s announced buyout of Virginia-based Landos Biopharma adds a mid-stage, oral NLRX1 agonist for ulcerative colitis and Crohn’s disease to AbbVie’s growing portfolio.
March 25, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: T cells attacking cancer/ iStock, Design
Clasp Emerges with $150M Series A Financing to Advance T Cell Engagers
Clasp Therapeutics announced Wednesday that the Series A funding, which was led in part by Novo Holdings, will support development of its T cell engagers for highly specific tumor targeting.
March 20, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Blood sample for insulin-like growth fac
Drug Development
Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission
The biotech Tuesday reported that 56% of patients taking paltusotine in a late-stage trial achieved the primary endpoint of IGF-1 levels for their rare hormonal disorder. An NDA submission is slated for later this year with a launch anticipated in 2025.
March 19, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Bristol Myers Squibb office in California
Business
BMS Bails on Checkpoint Inhibitor Teaming with CytomX, Stock Sinks
Bristol Myers Squibb has pulled the plug on a more potent version of its cancer immunotherapy Yervoy. However, the two companies will continue to work on other collaborative programs for T-cell engagers.
March 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Incyte's logo on its building in Delaware
Drug Development
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Incyte’s povorcitinib met both primary and secondary endpoints to relieve itching and improve skin clearance by 16 weeks, suggesting efficacy that is competitive with Sanofi and Regeneron’s blockbuster Dupixent.
March 11, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: An FDA blue van drives towards cardiac-s
Policy
Regulatory Pathway Widening for Cardiac Gene Therapy Hopefuls
Separate challenges exist for companies developing gene therapies for rare and common cardiovascular conditions, experts told BioSpace.
March 6, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Blue molecular design/iStock, Vichly44
BlossomHill Raises $100M in Series B, Focuses on Small Molecule Design
CEO J. Jean Cui’s track record has investors flocking to BlossomHill Therapeutics, after her last company—Turning Point Therapeutics—was sold to Bristol Myers Squibb in a $4.1 billion deal.
February 29, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Syringe drawing vaccine from a vial
Business
Novavax Q4 Revenue and Earnings Miss Estimates, Stock Drops Over 25%
The vaccine maker’s fourth-quarter revenue and earnings on Wednesday missed Wall Street expectations, while providing full-year 2024 sales guidance of flat to lower than last year.
February 28, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Denali Headquarters/iStock, hapabapa
Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics
On the heels of layoffs, Denali Therapeutics has entered into a securities purchase agreement with existing accredited investors as it spins off preclinical small molecule portfolio.
February 27, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Businessmen handshake/iStock, metamorwor
Drug Development
VC Firm’s New $260M Fund Taps AI to Identify Biotechs Poised for Success
ORI Capital announced Thursday that it has raised more than a quarter of a billion dollars for its second life sciences fund, which will invest in early-stage biotech companies using the firm’s proprietary AI-driven platform.
February 22, 2024
 · 
2 min read
 · 
Kate Goodwin
FDA signage at its office in Maryland
Policy
United Therapeutics Files Lawsuit Against FDA to Keep Exclusivity in PH-ILD Market
The litigation alleges the regulator allowed its competitor Liquidia to skirt FDA precedents by amending an already pending NDA to add a PH-ILD indication instead of filing a new application.
February 21, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Eli Lilly World Headquarters/iStock, jet
Business
Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023
Two surprise companies, Vertex Pharmaceuticals and Regeneron Pharmaceuticals, made GlobalData’s list with 41.4% and 21.8% market capitalization growth, respectively.
February 20, 2024
 · 
3 min read
 · 
Kate Goodwin
Pictured: Doctor with tape measure/iStock, Grandbr
Drug Development
BioAge Raises $170M in Series D for Obesity Drug Trial with Lilly’s Zepbound
The startup will use the money to fund a Phase II trial in combination with Eli Lilly’s Zepbound in the hopes of increased weight loss results, while attempting to protect body composition from muscle wasting.
February 13, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Wall Street Sign in NYC/iStock, stu99
Deals
Preclinical Metagenomi Tests Surging Biotech IPO Market with Near $94M Offering
Despite not having a single candidate in the clinical stage, the Moderna-backed biotech is offering 6.25 million shares for $15 apiece in an initial public offering. Shares are expected to begin trading Friday.
February 9, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: U.S. Capitol Building, Washington DC
Policy
BMS, J&J and Merck CEOs Push Back in Senate Hearing on High Drug Prices
The CEOs of BMS, J&J and Merck testified Thursday before the Senate health committee that pharmacy benefit managers bear much of the blame for high pricing, while declining to commit to price cuts.
February 9, 2024
 · 
4 min read
 · 
Kate Goodwin
Load More